GLP-1 Medications and Depression/Anxiety

You’ve probably seen the headlines. “Weight loss drugs linked to suicidal thoughts.” “FDA investigates psychiatric risks.” If you saw those before starting a GLP-1 medication — or while already taking one — they probably scared you. They scared a lot of people.

Here’s where we stand in 2026: the FDA, the European Medicines Agency, and the UK’s health regulator all investigated those concerns. The result? Not only did they find no causal link — the FDA actually requested the removal of suicidal behavior warnings from several GLP-1 medication labels. The data went in the opposite direction from what the headlines suggested.

But this isn’t a page that says “don’t worry about it.” Mental health is too important for that. What the research tells us is genuinely reassuring — and I’m going to walk you through it in detail. But the research also has limits, and your individual experience still matters. Both things can be true at the same time.

What the FDA Actually Found

In January 2026, the FDA published the results of a massive investigation: a meta-analysis of 91 placebo-controlled clinical trials involving 107,910 patients. They were looking specifically for evidence that GLP-1 medications increased the risk of suicidal ideation or behavior.[1]

They didn’t find it.

The data showed no increased risk compared to placebo. Based on that review, the FDA took the unusual step of requesting that manufacturers remove the suicidal behavior warning from the labels of Saxenda, Wegovy, and Zepbound. That’s significant — the FDA doesn’t remove warnings lightly. They do it when the evidence clearly doesn’t support keeping them.

The European Medicines Agency reached the same conclusion independently in 2024, as did the UK’s Medicines and Healthcare products Regulatory Agency. Three separate regulatory bodies, reviewing the evidence from different angles, all arrived at the same answer.[2]

The Research That Goes Further

The regulatory findings are reassuring on their own. But the research goes beyond “no harm found” — multiple studies suggest these medications may actually improve mental health outcomes.

From my experience, reading through this data was one of those moments where the evidence genuinely surprised me. I’d seen the headlines. I’d had the worry. And then the actual research said something completely different — not just “it’s fine,” but “it might actually help.”

The Honest Counterpoint

Good science means looking at all the data, not just the data that tells a comfortable story. And there is a study that tells a different one.

A large observational study published in Scientific Reports in 2024 analyzed data from 11.6 million adults and found a significant association between GLP-1 use and increased psychiatric diagnoses — including a 195% increased risk of major depression diagnosis and a 108% increased risk of anxiety diagnosis.[8]

That sounds alarming. But context matters enormously here.

This was an observational study, not a randomized controlled trial. People on GLP-1 medications see their doctors more often than the general population — more visits means more opportunities to be screened, diagnosed, and documented. Researchers call this ascertainment bias: when one group is being monitored more closely, they naturally accumulate more diagnoses, even if the actual rates of the condition are the same.

It’s the same reason people who get annual physicals have more diagnoses on their chart than people who avoid the doctor — not because they’re sicker, but because someone is actually looking.

This study directly contradicts the findings from multiple randomized controlled trials and larger cohort studies — the kinds of studies specifically designed to avoid the biases that observational data can’t control for. It doesn’t establish causation. But it’s worth knowing about, because you might encounter it, and dismissing it entirely wouldn’t be fair.

Why Mood Can Change in Both Directions

If the clinical data is largely reassuring, why do some people genuinely experience mood changes on GLP-1 medications? Because there are real mechanisms working in both directions.

Reasons Mood May Improve

Direct brain effects. GLP-1 receptors exist throughout the brain, including areas involved in mood regulation. Research shows these medications reduce neuroinflammation and may increase BDNF — a protein involved in brain cell health that works through some of the same pathways as antidepressants.[3]

Reduced food noise. The constant mental chatter about food — what to eat, when to eat, the guilt after eating — takes up enormous cognitive bandwidth. When that quiets down, many people describe a sense of mental relief they didn’t even know they needed.

Physical improvements. Better sleep, more mobility, less joint pain, improved lab values — all of these contribute to better mood. It’s hard to feel good emotionally when your body is struggling physically.

Quality of life gains. Fitting into clothes, moving more easily, feeling more confident — these improvements are real and they matter for mental health.

Reasons Mood May Worsen

Loss of a coping mechanism. As we covered earlier in this section, food serves as emotional regulation for many people. When that’s suddenly gone, the underlying emotions don’t go with it. Stress, sadness, anxiety — they’re all still there, just without the buffer.

Identity disruption. Rapid body changes can trigger a kind of psychological whiplash. Your reflection doesn’t match your self-image. People treat you differently. The adjustment isn’t always smooth.

Caloric restriction effects. Significantly reduced food intake can affect neurotransmitter levels — the brain chemicals involved in mood. This isn’t unique to GLP-1 medications. It happens with any significant caloric reduction.

GI side effects. Persistent nausea, vomiting, or GI distress takes a toll on anyone’s mood. Feeling physically miserable makes everything harder emotionally.

Social pressure and judgment. The stigma conversation we covered in this section? It’s real, and it affects mental health. Being told you’re “taking the easy way out” or facing judgment from people you care about adds a psychological burden.

None of these mean the medication is causing depression. They mean that a major life change — which is what starting a GLP-1 medication is — comes with emotional complexity. That’s normal. It’s also manageable, especially when you’re aware it might happen.

The Important Caveat About Clinical Trials

Here’s something the reassuring data doesn’t always make clear: the major clinical trials — STEP, SURMOUNT, SELECT — excluded participants with significant active depression, unstable psychiatric conditions, or severe mental illness within the previous two years.

That means the strongest safety data applies primarily to people without existing severe mental health conditions. It doesn’t mean the medications are unsafe for people with depression or anxiety — it means we have less data for that specific population.

This gap is starting to close. A 2025 randomized controlled trial — the first specifically conducted in people with major depressive disorder — found that semaglutide was safe in that population, with no worsening of depressive symptoms.[9]

That’s one study, and it’s a start. But if you have a history of depression, anxiety, or any other mental health condition, your provider needs to know about it. Not because it’s a reason to avoid GLP-1 medications — the evidence doesn’t support that conclusion. But because your mental health deserves monitoring regardless of what you’re taking.

If You're Already on Antidepressants

This comes up a lot: “Is it safe to take a GLP-1 medication if I’m already on an antidepressant?”

An analysis of 539 participants in the STEP trials who were taking antidepressants at baseline found that weight loss was comparable regardless of antidepressant use. Adverse events were similar too. There was no signal that combining a GLP-1 medication with antidepressants created additional risk.[10]

That’s reassuring. But it’s also not a substitute for telling your provider what you’re taking. Drug interactions are always worth reviewing — not just between GLP-1 medications and antidepressants, but between everything in your medication list.

The Bottom Line

The headlines were scary. The evidence tells a different story.

Three major regulatory agencies investigated the concern about GLP-1 medications and suicidality and found no link. The largest meta-analyses show no increase in psychiatric adverse events — and multiple studies show improvements in depression scores, quality of life, and emotional eating. The FDA was confident enough to remove the warning from the labels entirely.

That doesn’t mean your mental health doesn’t matter while you’re on these medications. It matters enormously — and it deserves active attention, not just passive reassurance. Mood can shift in both directions during a major life change like this, and some of the reasons have nothing to do with the medication itself.

The data is overwhelmingly reassuring. Your individual experience still deserves monitoring. Those aren’t contradictions — they’re both true, and a good provider will treat them that way.